Kisspeptin
Kisspeptin is a KISS1-gene-derived neuropeptide that acts as a central regulator of the reproductive hormone axis. Signalling through its receptor KISS1R (also called GPR54), it sits upstream of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. The most commonly used research form is kisspeptin-10, a 10-amino-acid fragment retaining full receptor activity. It is studied primarily in academic and clinical-physiology settings and is not an approved therapy for any condition.
Side effects & risks
Kisspeptin's safety profile in humans is drawn largely from short-term research settings, so longer-term and real-world risks are not well characterised. In controlled studies it has generally been reported as well tolerated at investigational doses, with injection-site reactions among the more commonly noted effects. Because kisspeptin directly stimulates the reproductive hormone axis, the principal caution is unintended hormonal effects: shifts in LH, FSH, and sex steroids that could disrupt menstrual cycles, fertility, or endocrine balance. It should be regarded as contraindicated in pregnancy, in those trying to conceive without medical guidance, and in anyone with a hormone-sensitive condition or an untreated endocrine disorder, given the lack of safety data. Interactions with fertility treatments and other hormonal medications are plausible but poorly studied. Effects on mood and other centrally mediated processes have been noted in research and are not fully understood. These risks and side effects appear here above the fold because they are integral to understanding the peptide, not a footnote. Anyone considering kisspeptin should consult a qualified clinician before use, as it is neither an approved therapy nor validated for self-administration.
Latest studies
The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54.
In engineered cells expressing the human kisspeptin receptor, a synthetic analog (C6) produced more sustained signaling and stronger desensitization than kisspeptin-10 and kisspeptin-54. The three agonists showed distinct pharmacological profiles.
Atrazine alters kisspeptin signaling and downstream neuroendocrine regulation following embryonic exposure in zebrafish.
In zebrafish, embryonic exposure to the herbicide atrazine reduced kisspeptin expression in the brain and altered downstream reproductive-hormone signaling and behavior. The study examines kisspeptin as an endogenous pathway disrupted by a toxicant, not as an administered peptide.
Neurotransmitter and neuromodulator imbalance in kisspeptin/GnRH regulation in rodent models of polycystic ovary syndrome and its implications for mental health disorders: A systematic review.
This systematic review of rodent PCOS models examines how kisspeptin and other neurotransmitter systems signal to GnRH neurons, and how these pathways may connect reproduction and mood. Kisspeptin is treated as an endogenous signaling pathway rather than an administered peptide.
Reported protocols (with caveats)
Reported use is confined to research and investigational settings, and kisspeptin is described as research use only. In published human physiology studies, kisspeptin-10 has most often been given intravenously as a bolus or continuous infusion, with doses frequently reported in the range of roughly 0.3 to a few micrograms per kilogram, allowing precise control of exposure. Some studies and community reports describe subcutaneous injection as an alternative route. Frequency in the literature varies from single acute challenges to repeated or pulsatile dosing designed to mimic natural GnRH pulses. Because these protocols come from controlled research environments with monitoring, they are not directly transferable to unsupervised use and are reported here for informational purposes only, never as a recommendation.